In a patient in their late 80s with a creatinine clearance of 18 mL/min and an HbA1c of 9.2%, what medications should be prescribed for diabetes management?

Medication Recommendations for Late 80s Patient with CrCl 18 and HbA1c 9.2%

In this very elderly patient with severe CKD (CrCl 18 mL/min) and poor glycemic control (HbA1c 9.2%), start basal insulin as the primary agent, with consideration of adding dapagliflozin 10 mg daily for cardiorenal protection if the patient is not frail.

Glycemic Target Considerations

First, recognize that an HbA1c of 9.2% is above any reasonable target for this patient. For very elderly patients with severe CKD (eGFR <30 mL/min), the target HbA1c should be 7.5-8.4% 1. This is critical because low eGFR (<30 mL/min) is an independent high-risk factor for severe hypoglycemia, even in patients with normal cognitive function and activities of daily living 1.

Primary Treatment: Basal Insulin

Basal insulin is the most appropriate first-line agent for several reasons:

• Once-daily basal insulin (glargine, detemir, degludec) is associated with minimal side effects and is reasonable in older patients 2
• At this level of kidney dysfunction (CrCl 18), insulin requires conservative initiation and titration to avoid hypoglycemia 3
• The glucose-lowering efficacy is preserved even at low eGFR, unlike many oral agents
• Start conservatively and titrate slowly based on fasting glucose goals of 90-150 mg/dL 2

Critical Insulin Dosing Caveat

Avoid aggressive dosing. In very elderly patients with severe CKD, even those with HbA1c >9%, approximately 50% had HbA1c levels below recommended ranges when treated intensively, indicating overtreament risk 1. Titrate by 2 units every week based on fasting glucose patterns 2.

Secondary Agent: SGLT2 Inhibitor (Dapagliflozin)

Consider adding dapagliflozin 10 mg daily for cardiorenal protection 3:

• Dapagliflozin is specifically approved for use with eGFR 25 to <45 mL/min at 10 mg once daily 3
• Critically, it may be continued even below eGFR 20 mL/min if tolerated, for kidney and cardiovascular benefit until dialysis 3
• At CrCl 18 (approximately eGFR 18-20), initiation is not recommended per package insert, but the 2022 ADA/KDIGO consensus states it can be continued if already started 3
• Glucose-lowering efficacy is reduced at this eGFR, but kidney and cardiovascular benefits are preserved 3

SGLT2 Inhibitor Precautions

Monitor for:

• Euglycemic ketoacidosis (especially if using insulin—maintain at least low-dose insulin and pause SGLT2i during acute illness) 3
• Genital mycotic infections (6% vs 1% placebo, higher in women) 3
• Volume depletion (though absolute risk is low even at low eGFR) 3

Agents to AVOID

Metformin is contraindicated at CrCl 18 mL/min 3. Despite being first-line in most patients, it should not be used below eGFR 30 mL/min due to lactic acidosis risk. Recent 2026 data specifically shows metformin in very elderly patients with CKD was associated with higher risk of ICU admission (HR 2.33), RRT initiation (HR 1.90), and lactic acidosis (HR 3.14) 4.

Sulfonylureas and glinides carry excessive hypoglycemia risk in this population and should be avoided 1, 5. If already prescribed, they should be discontinued.

Most DPP-4 inhibitors require dose reduction:

• Sitagliptin: maximum 25 mg daily at this eGFR 3
• Alogliptin: maximum 6.25 mg daily 3
• Saxagliptin: maximum 2.5 mg daily 3
• Linagliptin: no dose adjustment needed 3

However, DPP-4 inhibitors are not the priority here given the high HbA1c and need for more robust glucose lowering plus cardiorenal protection.

GLP-1 Receptor Agonists

GLP-1 RAs have mixed recommendations at this eGFR:

• Dulaglutide, liraglutide, and semaglutide require no dose adjustment 3
• Exenatide should be avoided (once-weekly formulation contraindicated) 3
• Lixisenatide is not recommended at eGFR <30 3

While GLP-1 RAs can provide excellent glucose lowering (potentially superior to basal insulin at high HbA1c levels 6), their use at CrCl 18 is more limited by renal dosing restrictions compared to insulin.

Practical Algorithm

1. Start basal insulin (e.g., glargine U-100) at 10 units once daily in the morning
2. Titrate by 2 units weekly targeting fasting glucose 90-150 mg/dL 2
3. If patient is not frail and can tolerate: Add dapagliflozin 10 mg daily for cardiorenal protection (recognizing this is off-label for initiation at this eGFR but supported by consensus guidelines for continuation) 3
4. Monitor closely for hypoglycemia (check glucose before meals, target 90-150 mg/dL) 2
5. Reduce insulin dose by 2 units if >2 readings/week are <80 mg/dL 2
6. Target HbA1c of 7.5-8.4% given age and severe CKD 1

Key Pitfall to Avoid

The greatest risk is overtreatment leading to severe hypoglycemia. Very elderly patients with eGFR <30 mL/min have a 50% chance of being overtreated even when following standard guidelines 1. Recent 2026 data confirms that vulnerable older adults with high comorbidity burden have substantially higher risk of severe hypoglycemia (IRR 2.71), and 76.9% of category III patients on insulin/sulfonylureas/glinides had HbA1c below the recommended lower limit of 7.5% 7.